everolimus + panobinostat

This is a combination of two small molecule drugs used primarily in oncology research: - **Everolimus (RAD001)** is an orally available inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), a key regulator of cell growth and proliferation. By inhibiting mTORC1, everolimus blocks downstream signaling pathways involved in protein synthesis and cell cycle progression. - **Panobinostat (LBH589)** is a potent, non-selective histone deacetylase (HDAC) inhibitor that induces hyperacetylation of histones and other proteins. This leads to altered gene expression, inhibition of tumor cell proliferation, induction of apoptosis via both intrinsic and extrinsic pathways, and disruption of multiple survival signaling cascades[2][3][4][5]. The combination has shown synergistic anti-tumor activity in preclinical models—particularly multiple myeloma—by inducing G0/G1 arrest (everolimus) and pronounced apoptosis (panobinostat), with modulation across several cellular survival pathways[2]. Both drugs are developed by Novartis.

Brand names

AfinitorFarydak

Other names

NVP-BEZ235NVP-BEZ-235NVP-BEZ 235NVP-LBH589NVP-LBH-589NVP-LBH 589